U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H10N4O2
Molecular Weight 194.1909
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CAFFEINE

SMILES

Cn1cnc2c1c(=O)n(C)c(=O)n2C

InChI

InChIKey=RYYVLZVUVIJVGH-UHFFFAOYSA-N
InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3

HIDE SMILES / InChI

Molecular Formula C8H10N4O2
Molecular Weight 194.1909
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://www.webmd.com/vitamins-supplements/ingredientmono-979-caffeine.aspx?activeingredientid=979

Caffeine is used by mouth or rectally in combination with painkillers (such as aspirin and acetaminophen) and a chemical called ergotamine for treating migraineheadaches. It is also used with painkillers for simple headaches and preventing and treating headaches after epidural anesthesia. Caffeine creams are applied to the skin to reduce redness and itching in dermatitis. Healthcare providers sometimes give caffeine intravenously (by IV) for headache after epidural anesthesia, breathing problems in newborns, and to increase urine flow. In foods, caffeine is used as an ingredient in soft drinks, energy drinks, and other beverages.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CAFERGOT

Approved Use

Ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The compound also has the properties of serotonin antagonism. In comparison to hydrogenated ergotamine, the adrenergic blocking actions are less pronounced and vasoconstrictive actions are greater. Caffeine, also a cranial vasoconstrictor, is added to further enhance the vasoconstrictive effect without the necessity of increasing ergotamine dosage.

Launch Date

-665798400000
Primary
CAFCIT

Approved Use

Caffeine Citrate injection USP is indicated for the short-term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age.

Launch Date

937785600000
Primary
Primary
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.35 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CAFFEINE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
65.64 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CAFFEINE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
43000 nM*h
100 mg single, oral
dose: 100 mg
route of administration: oral
experiment type: single
co-administered:
CAFFEINE plasma
Homo sapiens
population: healthy
age: adults
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.19 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CAFFEINE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
12.4 g single, oral
Overdose
Dose: 12.4 g
Route: oral
Route: single
Dose: 12.4 g
Sources:
unknown, 14 years
Health Status: unknown
Age Group: 14 years
Sex: F
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (1 patient)
Vomiting (1 patient)
Sources:
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Sources:
unknown, 27 years
Health Status: unknown
Age Group: 27 years
Sex: F
Sources:
Other AEs: Tachycardia, Seizure...
Other AEs:
Tachycardia (1 patient)
Seizure (1 patient)
Sources:
5000 mg single, oral
Overdose
Dose: 5000 mg
Route: oral
Route: single
Dose: 5000 mg
Sources:
healthy, 32 years
Health Status: healthy
Age Group: 32 years
Sex: F
Sources:
Other AEs: Malaise, Anxiety...
Other AEs:
Malaise (1 patient)
Anxiety (1 patient)
Dizziness (1 patient)
Nausea (1 patient)
Sources:
4000 mg single, oral
Overdose
Dose: 4000 mg
Route: oral
Route: single
Dose: 4000 mg
Sources:
pregnant, 33 years
Health Status: pregnant
Age Group: 33 years
Sex: F
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (1 patient)
Vomiting (1 patient)
Sources:
1.6 g single, oral
Overdose
Dose: 1.6 g
Route: oral
Route: single
Dose: 1.6 g
Sources:
healthy, 44 years
Health Status: healthy
Age Group: 44 years
Sex: M
Sources:
Other AEs: Atrial fibrillation...
Other AEs:
Atrial fibrillation (1 patient)
Sources:
800 mg multiple, oral
Highest studied dose
Dose: 800 mg
Route: oral
Route: multiple
Dose: 800 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sources:
24 g single, oral
Overdose
Dose: 24 g
Route: oral
Route: single
Dose: 24 g
Sources:
unknown, adult
Health Status: unknown
Age Group: adult
Sex: M
Sources:
Other AEs: Rhabdomyolysis, Acute renal failure...
Other AEs:
Rhabdomyolysis (1 patient)
Acute renal failure (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Nausea 1 patient
12.4 g single, oral
Overdose
Dose: 12.4 g
Route: oral
Route: single
Dose: 12.4 g
Sources:
unknown, 14 years
Health Status: unknown
Age Group: 14 years
Sex: F
Sources:
Vomiting 1 patient
12.4 g single, oral
Overdose
Dose: 12.4 g
Route: oral
Route: single
Dose: 12.4 g
Sources:
unknown, 14 years
Health Status: unknown
Age Group: 14 years
Sex: F
Sources:
Seizure 1 patient
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Sources:
unknown, 27 years
Health Status: unknown
Age Group: 27 years
Sex: F
Sources:
Tachycardia 1 patient
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Sources:
unknown, 27 years
Health Status: unknown
Age Group: 27 years
Sex: F
Sources:
Anxiety 1 patient
5000 mg single, oral
Overdose
Dose: 5000 mg
Route: oral
Route: single
Dose: 5000 mg
Sources:
healthy, 32 years
Health Status: healthy
Age Group: 32 years
Sex: F
Sources:
Dizziness 1 patient
5000 mg single, oral
Overdose
Dose: 5000 mg
Route: oral
Route: single
Dose: 5000 mg
Sources:
healthy, 32 years
Health Status: healthy
Age Group: 32 years
Sex: F
Sources:
Malaise 1 patient
5000 mg single, oral
Overdose
Dose: 5000 mg
Route: oral
Route: single
Dose: 5000 mg
Sources:
healthy, 32 years
Health Status: healthy
Age Group: 32 years
Sex: F
Sources:
Nausea 1 patient
5000 mg single, oral
Overdose
Dose: 5000 mg
Route: oral
Route: single
Dose: 5000 mg
Sources:
healthy, 32 years
Health Status: healthy
Age Group: 32 years
Sex: F
Sources:
Nausea 1 patient
4000 mg single, oral
Overdose
Dose: 4000 mg
Route: oral
Route: single
Dose: 4000 mg
Sources:
pregnant, 33 years
Health Status: pregnant
Age Group: 33 years
Sex: F
Sources:
Vomiting 1 patient
4000 mg single, oral
Overdose
Dose: 4000 mg
Route: oral
Route: single
Dose: 4000 mg
Sources:
pregnant, 33 years
Health Status: pregnant
Age Group: 33 years
Sex: F
Sources:
Atrial fibrillation 1 patient
1.6 g single, oral
Overdose
Dose: 1.6 g
Route: oral
Route: single
Dose: 1.6 g
Sources:
healthy, 44 years
Health Status: healthy
Age Group: 44 years
Sex: M
Sources:
Acute renal failure 1 patient
24 g single, oral
Overdose
Dose: 24 g
Route: oral
Route: single
Dose: 24 g
Sources:
unknown, adult
Health Status: unknown
Age Group: adult
Sex: M
Sources:
Rhabdomyolysis 1 patient
24 g single, oral
Overdose
Dose: 24 g
Route: oral
Route: single
Dose: 24 g
Sources:
unknown, adult
Health Status: unknown
Age Group: adult
Sex: M
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
weak (co-administration study)
Comment: When caffeine was coadministered the Cmax of melatonin was increased on average by 137% and AUC by 120%
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
likely (co-administration study)
Comment: lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin)
Page: 7
yes
yes
yes
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Cocaine-seeking produced by experimenter-administered drug injections: dose-effect relationships in rats.
1999 Dec
Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes--a new, selective antagonist radioligand for A(2A) adenosine receptors.
2000
Methadone, ciprofloxacin, and adverse drug reactions.
2000 Dec 16
Caffeine withdrawal increases cerebral blood flow velocity and alters quantitative electroencephalography (EEG) activity.
2000 Jan
Treatment of pentobarbitol sodium (Nembutal) hyperactivity: a new approach.
2000 Mar
Caffeine-potentiated radiochemotherapy and function-saving surgery for high-grade soft tissue sarcoma.
2000 May-Jun
Regulation of in vitro penetration of frozen-thawed boar spermatozoa by caffeine and adenosine.
2001 Apr
An apoplastic Ca2+ sensor regulates internal Ca2+ release in aequorin-transformed tobacco cells.
2001 Apr 6
Combined effects of red pepper and caffeine consumption on 24 h energy balance in subjects given free access to foods.
2001 Feb
BK channel activation by NS-1619 is partially mediated by intracellular Ca2+ release in smooth muscle cells of porcine coronary artery.
2001 Feb
Selected contribution: effect of the aldehyde acrolein on acetylcholine-induced membrane current in airway smooth muscle cells.
2001 Feb
Uric acid inhibits liver phosphorylase a activity under simulated in vivo conditions.
2001 Feb
The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.
2001 Feb 13
Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells.
2001 Feb 15
Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis.
2001 Jan
Clinical correlations in infants in the neonatal intensive care unit with varying severity of gastroesophageal reflux.
2001 Jan
Risk factors for sleep bruxism in the general population.
2001 Jan
Number of K(Ca) channels underlying spontaneous miniature outward currents (SMOCs) in mudpuppy cardiac neurons.
2001 Jan
The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat.
2001 Jan 12
The nuclear death domain protein p84N5 activates a G2/M cell cycle checkpoint prior to the onset of apoptosis.
2001 Jan 12
Origin and propagation of spontaneous excitation in smooth muscle of the guinea-pig urinary bladder.
2001 Jan 15
Acute but not chronic caffeine impairs functional responses to ischaemia-reperfusion in rat isolated perfused heart.
2001 Jan-Feb
Low-dose ramipril treatment improves relaxation and calcium cycling after established cardiac hypertrophy.
2001 Mar
Regulation of slow wave frequency by IP(3)-sensitive calcium release in the murine small intestine.
2001 Mar
Study of the cytolethal distending toxin (CDT)-activated cell cycle checkpoint. Involvement of the CHK2 kinase.
2001 Mar 2
Escape deficits induced by inescapable shock and metabolic stress are reversed by adenosine receptor antagonists.
2001 May
Patents

Sample Use Guides

Caffeine is used by mouth in combination with painkillers (such as aspirin and acetaminophen) for treating headaches. Maximum oral dose of excedrin is 2 tablets a day (each tablet of excedrin contains 65 mg of caffeine). Caffeine creams are applied to the skin to reduce redness and itching in dermatitis. Healthcare providers sometimes give caffeine intravenously (by IV) for headache after epidural anesthesia, breathing problems in newborns, and to increase urine flow. In foods, caffeine is used as an ingredient in soft drinks, energy drinks, and other beverages.
Route of Administration: Other
In Vitro Use Guide
Binding of caffeine to adrenergic receptors was measured using [3H]N6-Cyclohexyladenosine as a radioligand. Nonspecificbinding was less than 10% of total binding as defined with 10 uM 2-chloroadenosine. Membranes were incubated with 10-6 - 10-3 M caffeine.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:09:16 UTC 2021
Edited
by admin
on Fri Jun 25 21:09:16 UTC 2021
Record UNII
3G6A5W338E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CAFFEINE
EP   FCC   FHFI   HSDB   II   INCI   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD   WHO-IP  
INCI  
Official Name English
FEMA NO. 2224
Code English
CAFFEINE [II]
Common Name English
TREZIX COMPONENT CAFFEINE
Brand Name English
CAFFEINE [FCC]
Common Name English
CAFFEINE COMPONENT OF CAFERGOT
Common Name English
CAFFEINE [WHO-DD]
Common Name English
CAFFEINE [HSDB]
Common Name English
CAFFEINE COMPONENT OF NORGESIC
Common Name English
THEOPHYLLINE MONOHYDRATE IMPURITY A [EP]
Common Name English
CAFFEINE ANHYDROUS [WHO-IP]
Common Name English
CAFFEINE COMPONENT OF FIORINAL
Common Name English
FEMCET COMPONENT CAFFEINE
Common Name English
THEOPHYLLINE IMPURITY A [EP]
Common Name English
FIORINAL COMPONENT CAFFEINE
Common Name English
1H-PURINE-2,6-DIONE, 3,7-DIHYDRO-1,3,7-TRIMETHYL-
Systematic Name English
SYNALGOS
Common Name English
INVAGESIC COMPONENT CAFFEINE
Common Name English
DIMENHYDRINATE IMPURITY C [EP]
Common Name English
CAFERGOT COMPONENT CAFFEINE
Common Name English
CAFFEINE [ORANGE BOOK]
Common Name English
SYNALGOS-DC COMPONENT CAFFEINE
Common Name English
CAFFEINUM [HPUS]
Common Name English
VIVARIN
Common Name English
ORPHENGESIC COMPONENT CAFFEINE
Common Name English
CAFFEINE COMPONENT OF LANORINAL
Common Name English
THEINE
Common Name English
CAFFEINE COMPONENT OF ORPHENGESIC
Common Name English
MIGERGOT COMPONENT CAFFEINE
Common Name English
GUARANINE
Common Name English
CAFFEINE COMPONENT OF SYNALGOS-DC-A
Common Name English
DHC PLUS COMPONENT CAFFEINE
Common Name English
PENTOXIFYLLINE IMPURITY F [EP]
Common Name English
CAFFEINE COMPONENT OF FIORICET
Common Name English
TRIAD COMPONENT CAFFEINE
Common Name English
CAFFEINE [USP-RS]
Common Name English
CAFFEINE COMPONENT OF INVAGESIC
Common Name English
INVAGESIC FORTE COMPONENT CAFFEINE
Common Name English
CAFFEINE [INCI]
Common Name English
CAFFEINE [FHFI]
Common Name English
ESGIC COMPONENT CAFFEINE
Common Name English
CAFFEINE COMPONENT OF TRIAD
Common Name English
NORGESIC COMPONENT CAFFEINE
Common Name English
SYNALGOS-DC-A COMPONENT CAFFEINE
Common Name English
COFFEINUM [WHO-IP LATIN]
Common Name English
CAFFEINE COMPONENT OF DHC PLUS
Common Name English
ANHYDROUS CAFFEINE
JAN  
Common Name English
CAFFEINE COMPONENT OF SYNALGOS-DC
Common Name English
CAFFEINE [VANDF]
Common Name English
CAFFEINE COMPONENT OF WIGRAINE
Common Name English
CAFFEINE COMPONENT OF ESGIC
Common Name English
DARVON COMPOUND COMPONENT CAFFEINE
Common Name English
CAFFEINE COMPONENT OF ORPHENGESIC FORTE
Common Name English
CAFFEINE [IARC]
Common Name English
ORPHENGESIC FORTE COMPONENT CAFFEINE
Common Name English
CAFFEINE COMPONENT OF EXCEDRIN
Common Name English
CAFFEINE COMPONENT OF INVAGESIC FORTE
Common Name English
CAFFEINE [EP MONOGRAPH]
Common Name English
CAFFEINUM
HPUS  
Common Name English
FIORICET COMPONENT CAFFEINE
Common Name English
MEDIGESIC PLUS COMPONENT CAFFEINE
Common Name English
METHYLTHEOBROMINE
Systematic Name English
CAFFEINE COMPONENT OF FEMCET
Common Name English
CAFFEINE COMPONENT OF DARVON COMPOUND
Common Name English
EXCEDRIN COMPONENT CAFFEINE
Common Name English
CAFFEINE COMPONENT OF MEDIGESIC PLUS
Common Name English
CAFFEINE [WHO-IP]
Common Name English
CAFFEINE COMPONENT OF MIGERGOT
Common Name English
CAFFEINE [MI]
Common Name English
NSC-5036
Code English
DIMENHYDRINATE IMPURITY C
EP  
Common Name English
ANHYDROUS CAFFEINE [JAN]
Common Name English
WIGRAINE COMPONENT CAFFEINE
Common Name English
CAFFEINE COMPONENT OF ANOQUAN
Common Name English
LANORINAL COMPONENT CAFFEINE
Common Name English
ANOQUAN COMPONENT CAFFEINE
Common Name English
CAFFEINE MELTING POINT STANDARD
USP-RS  
Common Name English
CAFFEINE [MART.]
Common Name English
1,3,7-TRIMETHYLXANTHINE
Systematic Name English
CAFFEINE [USP]
Common Name English
DURVITAN
Common Name English
Classification Tree Code System Code
WHO-VATC QV04CG30
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
NDF-RT N0000175729
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
CFR 21 CFR 340.10
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
NDF-RT N0000175790
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
WHO-VATC QN06BC01
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
NCI_THESAURUS C54060
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
NCI_THESAURUS C47795
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
NDF-RT N0000175739
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
IARC Caffeine
NDF-RT N0000008118
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
NDF-RT N0000008118
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
DSLD 367 (Number of products:3156)
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
FDA ORPHAN DRUG 367512
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
EPA PESTICIDE CODE 660
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
WHO-ATC V04CG30
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
FDA ORPHAN DRUG 31288
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
WHO-ATC N06BC01
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
LIVERTOX 137
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
CFR 21 CFR 340.50
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
Code System Code Type Description
LACTMED
Caffeine
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
MESH
D002110
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
RXCUI
1886
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY RxNorm
IUPHAR
407
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
CAFFEINE
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY Description: Silky, colourless crystals or a white, crystalline powder; odourless. Solubility: Soluble in 60 parts of water and in 100 parts of ethanol (~750 g/l) TS; slightly soluble in ether R. Category: Central nervous stimulant. Storage: Caffeine should be kept in a well-closed container. Labelling: The designation on the container of Caffeine should state whether the substance is the monohydrate or is in the anhydrous form. Additional information: Caffeine monohydrate is efflorescent in air. Definition: Caffeine contains not less than 98.5% and not more than 101.0% of C8H10N4O2, calculated with reference to the dried substance.
DRUG CENTRAL
463
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
DRUG BANK
DB00201
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL113
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
HSDB
35
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
USP_CATALOG
1085003
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY USP-RS
PUBCHEM
2519
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
WIKIPEDIA
CAFFEINE
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
NCI_THESAURUS
C328
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
USP_CATALOG
1086006
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY USP-RS
EPA CompTox
58-08-2
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
EVMPD
SUB26077
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-362-1
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
EVMPD
SUB13146MIG
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
CAS
58-08-2
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
MERCK INDEX
M2909
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY Merck Index
FDA UNII
3G6A5W338E
Created by admin on Fri Jun 25 21:09:16 UTC 2021 , Edited by admin on Fri Jun 25 21:09:16 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
Secondary metabolite detected in developing cacao seeds.
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PARENT
MINOR
PLASMA
METABOLITE -> PARENT
METABOLITE -> PARENT
IN-VIVO
URINE
PARENT -> METABOLITE ACTIVE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
MAIN PRIMARY METABOLITE; METABOLISM OCCURS IN LIVER
MAJOR
PLASMA; URINE
METABOLITE -> PARENT
Hepatic biotransformation prior to excretion results in about equal amounts of 1-methylxanthine and 1-methyluric acid.
METABOLITE -> PARENT
Human, oral
IN-VITRO
URINE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
http://apps.who.int/phint/pdf/b/Jb.6.1.66.pdf
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC